De Gusmao, CM;
Silveira-Moriyama, L;
(2019)
Paroxysmal movement disorders – practical update on diagnosis and management.
Expert Review of Neurotherapeutics
, 19
(9)
pp. 807-822.
10.1080/14737175.2019.1648211.
Preview |
Text
Accepted article.pdf - Accepted Version Download (434kB) | Preview |
Abstract
Introduction: Paroxysmal dyskinesias and episodic ataxias are often caused by mutations in genes related to cell membrane and synaptic function. Despite the exponential increase in publications of genetically confirmed cases, management remains largely clinical based on non-systematic evidence. / Areas covered: The authors provide a historical and clinical review of the main types of paroxysmal dyskinesias and episodic ataxias, with recommendations for diagnosis and management of patients suffering from these conditions. / Expert opinion: After secondary paroxysmal dyskinesias, the most common paroxysmal movement disorders are likely to be PRRT2-associated paroxysmal kinesigenic dyskinesias, which respond well to small doses of carbamazepine, and episodic ataxia type 2, which often responds to acetazolamide. Familial paroxysmal non-kinesigenic dyskinesias are largely caused by mutations in PNKD and have poor response to therapy but improve with age. Exercise-induced dyskinesias are genetically heterogeneous, caused by disorders of glucose transport, mitochondrial function, dopaminergic pathways or neurodegenerative conditions amongst others. GNAO1 and ADCY5 mutations can also cause paroxysmal movement disorders, often in the context of ongoing motor symptoms. Although a therapeutic trial is justified for classic cases and in limited resource settings, genetic testing may help direct initial or rescue therapy. Deep brain stimulation may be an option for severe cases.
Type: | Article |
---|---|
Title: | Paroxysmal movement disorders – practical update on diagnosis and management |
Location: | England |
Open access status: | An open access version is available from UCL Discovery |
DOI: | 10.1080/14737175.2019.1648211 |
Publisher version: | https://doi.org/10.1080/14737175.2019.1648211 |
Language: | English |
Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
Keywords: | Acetazolamide, antiepileptic drugs, episodic ataxias, paroxysmal dyskinesias, paroxysmal movement disorders |
UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology |
URI: | https://discovery.ucl.ac.uk/id/eprint/10079889 |
Archive Staff Only
![]() |
View Item |